Quick Takeaways
- ARCH Venture Fund IX, L.P. filed SCHEDULE 13G/A for Singular Genomics Systems, Inc. Common Stock par value $0.0001 per share (OMIC).
- Disclosed ownership: 0%.
- Date of event: 21 Feb 2025.
Quoteable Key Fact
"ARCH Venture Fund IX, L.P. disclosed 0% ownership in Singular Genomics Systems, Inc. Common Stock par value $0.0001 per share (OMIC) on 21 Feb 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 0% | 0 | 0 | 0 | ARCH Venture Partners IX, L.P. | its General Partner | |
| ARCH Venture Partners IX, L.P. | 0% | 0 | 0 | 0 | ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners IX, LLC | 0% | 0 | 0 | 0 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director | |
| Keith Crandell | 0% | 0 | 0 | 0 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Keith Crandell | |
| Clinton Bybee | 0% | 0 | 0 | 0 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Clinton Bybee | |
| Robert Nelsen | 0% | 0 | 0 | 0 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Robert Nelsen |